{"article_title": "'Superbug' scopes lacked FDA clearance; Feds ask hospitals not to cancel surgeries", "article_keywords": ["fda", "scopes", "duodenoscope", "superbug", "hospitals", "medical", "infections", "olympus", "ask", "feds", "tied", "cre", "cancel", "tjfq180v", "lacked", "clearance", "surgeries"], "article_url": "http://www.healthcarefinancenews.com/news/superbug-scopes-lacked-fda-clearance-feds-ask-hospitals-not-cancel-surgeries", "article_text": "The FDA said the Olympus TJF-Q180V duodenoscope, one of the scopes tied to the CRE cases, is still pending clearance while being marketed to hospitals.\n\nThe U.S. Food and Drug Administration is advising hospitals not to cancel procedures requiring duodenoscopes and said there is no evidence that the lack of federal clearance on one of the scopes tied to recent \u201csuperbug\u201d cases in California contributed to the infections.\n\nThe announcement comes one day after Cedars-Sinai Medical Center said four patients contracted CRE infections from organ scopes used to examine their liver, bile ducts or pancreas. In February, two people died from infections tied to similar scopes at UCLA's Ronald Reagan Medical Center.\n\n[Also: 'Superbug' infections hit Cedars-Sinai]\n\nThe FDA said the Olympus TJF-Q180V duodenoscope, one of the scopes tied to the CRE cases, is still pending clearance while being marketed to hospitals.\n\nFollow Healthcare Finance on Twitter and LinkedIn.\n\nPatients who need endoscopic retrograde cholangiopancreatography surgeries, or ERCP, should receive them, the FDA said, advising hospitals to disinfect any scopes they think may be tied to an infection.\n\nHowever, the FDA said distributors shouldn\u2019t shelve the Olympus scopes because that could cause a dangerous shortage of the devices. According to the FDA, duodenoscopes are used nationally in 500,000 procedures a year.\n\nAccording to CNN, the Olympus TJF-Q180V scope first hit the supply chain market in 2010 without asking for FDA clearance. However, the FDA didn\u2019t realize that until late 2013 or early 2014.\n\nOlympus said it did not believe clearance was needed.\n\n\u201cOlympus Medical Systems Corp. made a decision, based upon FDA policy, that a modification to our previously FDA cleared duodenoscope did not require a new 510(k) application to FDA prior to marketing the modified duodenoscope in the U.S. in 2010,\u201d the company said in a statement.\n\nTwitter: @HenryPowderly", "article_metadata": {"og": {"url": "http://www.healthcarefinancenews.com/news/superbug-scopes-lacked-fda-clearance-feds-ask-hospitals-not-cancel-surgeries", "image": "http://www.healthcarefinancenews.com/sites/healthcarefinancenews.com/files/surgical-supplies-feature_1.gif", "site_name": "Healthcare Finance News", "description": "The FDA said the Olympus TJF-Q180V duodenoscope, one of the scopes tied to the CRE cases, is still pending clearance while being marketed to hospitals.", "title": "'Superbug' scopes lacked FDA clearance; Feds ask hospitals not to cancel surgeries"}, "twitter": {"image": {"src": "http://www.healthcarefinancenews.com/sites/healthcarefinancenews.com/files/surgical-supplies-feature_1.gif"}, "title": "'Superbug' scopes lacked FDA clearance; Feds ask hospitals not to cancel surgeries", "description": "The FDA said the Olympus TJF-Q180V duodenoscope, one of the scopes tied to the CRE cases, is still pending clearance while being marketed to hospitals.", "card": "summary_large_image", "site": "@HC_Finance"}, "viewport": "width=device-width; initial-scale=1.0; maximum-scale=1.0; user-scalable=no", "description": "The U.S. Food and Drug Administration is advising hospitals not to cancel procedures requiring duodenoscopes and said there is no evidence that the lack of federal clearance on one of the scopes tied to recent \u201csuperbug\u201d cases in California contributed to the infections.", "generator": "Drupal 7 (http://drupal.org)"}, "_id": "\"57477af46914bd0286fdeb27\"", "article_summary": "According to CNN, the Olympus TJF-Q180V scope first hit the supply chain market in 2010 without asking for FDA clearance.\nThe FDA said the Olympus TJF-Q180V duodenoscope, one of the scopes tied to the CRE cases, is still pending clearance while being marketed to hospitals.\nHowever, the FDA said distributors shouldn\u2019t shelve the Olympus scopes because that could cause a dangerous shortage of the devices.\n[Also: 'Superbug' infections hit Cedars-Sinai]The FDA said the Olympus TJF-Q180V duodenoscope, one of the scopes tied to the CRE cases, is still pending clearance while being marketed to hospitals.\nIn February, two people died from infections tied to similar scopes at UCLA's Ronald Reagan Medical Center."}